Mixed Views on US Biosimilar Market

Much was expected of biosimilars and their potential to cut the price of originator with savings projected to reach hundreds of billions. Such expectation at least in the US have proven unrealistic. A report last year (2019) outlined that the US healthcare system barely make savings worth 7 billion dollars annually. AS 2020 makes its halfway, researchers begin to investigate biosimilars in the US to determine how successful their introduction onto the market could be.

Review the following reference and probe the questions below:

How many TFDA approved biosimilars are there on the Taiwan market? What is the reimbursement policy for biosimilars in Taiwan as dictated by the National Insurance of Health?